Novel lactic acid bacteria with anti-hyperuricemia ability: Screening and in vitro probiotic characteristics

Hyperuricemia has been identified as the second most common metabolic disease, increasing the incidence of gout, hypertension, kidney disease, and cardiovascular disease. Lactic acid bacteria have been attracting considerable interest in anti-hyperuricemia given various probiotic functions. In this study, sixteen lactic acid bacteria were selected from one hundred ninety-two isolates through whole-cell catalysis, affording β-D-glucosidase activity of 0.1652–0.3346 U/mg wet cells, degradation rate of inosine-transformed rate of 1.2125–4.6555 mM/h and guanosine-transformed rate of 0.2904–1.8303 mM/h. The sixteen candidates’ acid tolerance, bile resistance, hydrophobicity, and auto-aggregation were further evaluated. According to the results of the seven indexes, the five top-scored strains were viewed as the potentially functional probiotics for anti-hyperuricemia via the comprehensive evaluation of principal component analysis. Cell assay showed that the adhesion of the five strains to Caco-2 cells ranged from 2.67% to 8.67%. Moreover, the five strains can decrease the adhesion of E. coli to Caco-2 cells by 36.67–98.73% through competition inhibition, exclusion inhibition, and replacement inhibition. Finally, the five probiotics were sensitive to some of the antibiotics examined and were innocuous with nonhemolytic activity. The preliminary works indicate that the five candidates could show a good potential application against hyperuricemia. • 192 LAB strains were determined in anti-hyperuricemia ability. • The strains with anti-hyperuricemia ability and probiotic properties were evaluated by PCA. • The screened strains show excellent cell adhesion and inhibition of pathogen adhesion. • The antibiotic sensitivity and hemolytic activity of the screened LAB strains were investigated.